Vortioxetine Is A Novel Antidepressant With Multimodal Activity, Which Is Approved To Treat Major Depressive Disorder (Mdd) In Adults. Sun Pharma On Wednesday Said It Has Entered Into An Exclusive Patent Licensing Agreement With Danish-Drugmaker Lundbeck To Market And Distribute Its Own Version Of Antidepressant Medication Vortioxetine In India Under The Brand Name Vortidiftm. The Territory Of The Licensing Agreement Will Only Cover India. Vortioxetine Is A Novel Antidepressant With Multimodal Activity, Which Is Approved To Treat Major Depressive Disorder (Mdd) In Adults. The Product Is Approved In Over 80 Countries, Including The Us, Eu, Canada And Australia.
